Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Capecitabine in 2nd Line Pancreatic Cancer
NCT00881621Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Aug 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in pancreatic cancer (PC), sponsored by Georgetown University. Primary endpoint: Overall Survival at 24 months. Started Aug 2009; status: terminated.
02
Drugs
lapatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00881621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881621.